Opus Genetics (IRD) PT Lowered to $9 at RBC Capital

August 7, 2026 7:30 AM

RBC Capital analyst Lisa Walter lowered the price target on Opus Genetics (NASDAQ: IRD) to $9.00 (from $10.00) while maintaining a Outperform rating.

No results found